Syndax Pharmaceuticals stock (US88906L1052): Analyst upgrade drives 6.6% gain

Syndax Pharmaceuticals surged 6.6% on May 4 following an analyst upgrade, as the clinical-stage biotech advances its menin inhibitor pipeline with 12 abstracts accepted for EHA 2026.

Syndax Pharmaceuticals (NASDAQ: SNDX) stock rose 6.6% on May 4, 2026, following an analyst upgrade, according to MarketBeat as of May 4, 2026. The clinical-stage biopharmaceutical company, which focuses on developing novel cancer therapies, has gained momentum as it prepares to showcase its lead program Revuforj (revumenib) at the European Hematology Association conference.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Syndax Pharmaceuticals Inc.
• Sector/industry: Biopharmaceutical / Oncology
• Headquarters/country: United States
• Core markets: Acute myeloid leukemia (AML), other hematologic malignancies
• Key revenue drivers: Revuforj (revumenib) clinical development and potential commercialization
• Home exchange/listing venue: NASDAQ (SNDX)
• Trading currency: USD

Syndax Pharmaceuticals: clinical-stage oncology focus

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cancer treatment. The company's pipeline centers on menin inhibitors, a class of targeted therapies designed to address specific genetic drivers in hematologic malignancies. Revuforj (revumenib), the company's lead candidate, has advanced through clinical development with a focus on acute myeloid leukemia and other blood cancers. As a pre-commercial biotech, Syndax operates without significant product revenue, relying on capital markets and potential partnerships to fund ongoing research and development activities.

Revuforj pipeline and EHA 2026 presentation

Syndax announced that 12 abstracts related to Revuforj have been accepted for presentation at the European Hematology Association (EHA) 2026 conference, according to Business Insider as of May 2026. This scientific validation underscores the company's leadership position in menin inhibition research. The conference presentations represent a key milestone for communicating clinical data to the hematology and oncology community, potentially influencing investor sentiment and regulatory pathway discussions.

Analyst sentiment and valuation

Syndax carries a consensus rating of Moderate Buy from 13 analysts covering the stock, according to MarketBeat as of May 12, 2026. The consensus price target stands at $42.64, implying approximately 99.4% upside from the stock's trading level of $21.38 as of May 11, 2026. The rating composition includes 1 strong buy, 11 buy ratings, and 1 sell rating, reflecting generally constructive sentiment among research analysts. The wide spread between current price and consensus target reflects typical biotech valuation dynamics tied to clinical trial outcomes and regulatory milestones.

Recent financial performance

Syndax reported Q1 2026 earnings on April 30, 2026, posting an EPS of -$0.48, which beat the consensus estimate of -$0.59 by $0.11, according to MarketBeat as of May 12, 2026. The company's market capitalization stood at approximately $1.89 billion as of mid-May 2026. As a clinical-stage company, Syndax does not generate meaningful product revenue and operates with negative earnings, a typical profile for pre-commercial biopharmaceutical firms in development phases.

Conclusion

Syndax Pharmaceuticals represents a clinical-stage oncology play centered on menin inhibitor development, with Revuforj as its lead asset. The May 4 analyst upgrade and 6.6% stock gain reflect growing confidence in the company's pipeline advancement and scientific validation through EHA 2026 presentations. Investors should monitor clinical trial progress, regulatory interactions, and capital management as key drivers of future stock performance. The wide gap between current valuation and analyst price targets underscores the speculative nature typical of pre-commercial biotech investments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.